Conditions: Cholangiocarcinoma Hepatobiliary Neoplasm Liver Cancer Bile Duct Cancer Cancer of Gallbladder
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 2
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine progression-free survival at 12 months for stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar cholangiocarcinoma (CCA).

Detailed description:
Investigators hope to learn more about neoadjuvant SBRT and chemotherapy for unresectable CCA, and if SBRT followed by chemotherapy can lead to successful liver transplantation. This knowledge is important for this patient group as this disease is a highly lethal malignancy that often presents as unresectable, however surgery or transplantation are the only curative options.

Arms:
arm 1: The patients received Stereotactic Body Radiotherapy and Chemotherapy followed by a liver transplantation. The chemo could be any combination of the following: Gemcitabine, Cisplatin, Carboplatin, Capecitabine and 5FU

Interventions: intervention 1: Stereotactic Body Radiotherapy intervention 2: Gemcitabine intervention 3: Cisplatin intervention 4: Carboplatin intervention 5: Capecitabine intervention 6: 5FU intervention 7: Liver transplantation
Intervention descriptions: intervention 1: Standard of care intervention 2: 100 mg/m2, IV intervention 3: 25 mg/m2, IV intervention 4: AUC 2, based on Calvert formula, IV intervention 5: 1000 mg/m2, PO intervention 6: 200 mg/m2 intervention 7: None

Protocol document: